Vicore ASPIREs To Be Major IPF Player As Sanofi Jumps Onboard

The Swedish company is well positioned, and well financed with a bit of help from the French major, to push its idiopathic pulmonary fibrosis hopeful buloxibutid closer to the regulatory finishing line.